1. Introduction {#s0005}
===============

Over one third of patients with major depressive disorder are treatment-resistant and fail to respond to two or more antidepressant medications or psychotherapy ([@bb0100]; [@bb0015]). This trial-and-error approach can be overbearing for patients in terms of cost, as well as the emotional trauma associated with the prolonged treatment process ([@bb0105]). Such cases of treatment-resistant depression are also challenging for clinicians. Through the process of identifying an optimal treatment, patients may receive several courses of medication and each treatment course can significantly impact brain circuitry, regardless of clinical outcome ([@bb0120]; [@bb0240]; [@bb0235]; [@bb0185]). The complexity of these individual differences can further complicate the process of identifying an appropriate treatment for these patients. To date, electroconvulsive therapy (ECT) remains the most effective treatment for patients with treatment-resistant depression ([@bb0145]; [@bb0195]). Yet its mechanism of action is still not known.

It is hypothesized that the brief, generalized seizure triggered by ECT impacts the dynamics of brain networks disrupted in depression ([@bb0090]) but also networks involved in cognition, leading to its most common adverse effect: memory impairment ([@bb0085]). Magnetic seizure therapy (MST) ([@bb0230]) also relies on the principles of seizure induction for therapeutic benefit but unlike ECT, the effect of MST is localized ([@bb0070]). Based on the few clinical trials conducted to date, MST improves depressive symptoms ([@bb0175]; [@bb0180]; [@bb0055]) and suicidal ideation ([@bb0370]), without the cognitive side effects seen with ECT ([@bb0230]; [@bb0080]; [@bb0355]; [@bb0265]). However, in its early stage of development, its efficacy relative to ECT requires further study ([@bb0175]). Identifying brain networks affected by treatment-resistant depression and modified by ECT may allow the optimization of MST as well as the development of non-invasive and non-seizure inducing treatments.

Evidence from neuroimaging studies suggests that specific patterns of brain network dysfunction at rest may contribute to core deficits in cognitive and affective functions underlying neuropsychiatric disorders ([@bb0010]; [@bb0125]; [@bb0130]; [@bb0040]; [@bb0395]; [@bb0425]). It has also been shown that the resting-state of the brain can predict physiological consequences of brain stimulation and treatment outcome ([@bb0235]; [@bb0115]; [@bb0135]). Collectively, the temporal variation in resting-state brain network dynamics may be a significant marker of illness and therapeutic outcome ([@bb0160]; [@bb0045]; [@bb0150]). To advance the development of novel and targeted treatments, it is critical to characterize the disruption and changes in brain network dynamics in treatment-resistant depression and by successful treatments such as ECT ([@bb0005]; [@bb0280]; [@bb0305]).

Using electroencephalography (EEG), functional brain networks and their dynamics can be examined through microstate analysis, a data-driven approach used to measure the spatial stability of brain network dynamics over time ([@bb0220]; [@bb0285]; [@bb0250]). Microstate analysis clusters the topographical distributions of spontaneous EEG activity into a set of four classes (A, B, C and D as described in the method) of brain states (i.e., microstates) that each remain stable over a short period of time before transiting into another state (50--120 ms) ([@bb0365]). An increase in the duration of a microstate implies an increase in the probability of that microstate to be followed by itself. Since each microstate is generated by an underlying neuronal population, the temporal characteristics of a microstate (such as rate of change or duration) may be considered as an expression of the dynamic stability of underlying spatial networks ([@bb0030]). The duration of microstates is also consistent with the duration of high-level cognitive processes, as shown by evoked-potential studies ([@bb0215]). Moreover, microstates were shown to be state-dependent, to vary across age, cognitive state ([@bb0030]; [@bb0210]; [@bb0255]; [@bb0345]) and in response to therapy ([@bb0205]; [@bb0315]; [@bb0200]). Studies have also confirmed the reliability of microstates across repeated testing sessions ([@bb0190]).

Microstates were previously linked with brain networks identified through resting-state functional magnetic resonance imaging (fMRI) ([@bb0025]; [@bb0275]; [@bb0420]), some suggested to be impaired in depression ([@bb0170]; [@bb0110]; [@bb0390]; [@bb0405]). For example, microstates C and D were linked to the salience and frontoparietal networks ([@bb0025]) and the relative activation of these networks is hypothesized to be impaired in depression ([@bb0270]; [@bb0140]). However, to date, there has been only one study that examined and reported a decrease in duration of microstates in depression compared to healthy controls ([@bb0365]). This study was not in treatment-resistant patients and may not extend to treatment-resistant depression ([@bb0415]; [@bb0060]; [@bb0410]; [@bb0400]).

Collectively, the evidence in support of resting-state network abnormalities in depression ([@bb0170]; [@bb0110]; [@bb0390]; [@bb0405]), the sensitivity of microstates in detecting intervention-related changes in resting-state networks ([@bb0205]; [@bb0315]; [@bb0200]), and the consistency of microstates across repeated testing sessions ([@bb0190]), motivated the utility of EEG microstates in this study. Using the high temporal resolution of EEG to an advantage, we aimed to investigate the therapeutic impact of seizure therapy on network dynamics and the temporal stability of brain network dynamics between patients with treatment-resistant depression and healthy subjects.

Our primary hypotheses were two-fold: (a) microstates C and D, previously associated with the salience and frontoparietal networks implicated in depression, will be modulated by successful seizure therapy; (b) baseline and seizure therapy-induced changes in microstates will be associated with therapeutic outcome, and could explain changes in cognition and suicidal ideation. Our secondary hypothesis was that patients with treatment-resistant depression will present different microstate dynamics compared to healthy controls. These dynamics will be modulated by seizure therapy towards the healthy group dynamics.

2. Material and methods {#s0010}
=======================

2.1. Subjects {#s0015}
-------------

Data was collected from 75 patients (Age: μ = 45.7, σ = 14.4; 44 females) with a Structured Clinical Interview for the Diagnostic and Statistical Manual of mental disorders (DSM-IV) diagnosis of Major Depressive Disorder who previously did not respond to 2 or more antidepressants (i.e., treatment-resistant depression), and 55 healthy controls (Age: μ = 39.2, σ = 17.4; 29 females) with written informed consent. Of the 75 patients, follow-up assessments were conducted for 22 patients receiving ECT and 24 receiving MST. The remaining 29 patients either did not provide their consent for follow-up or withdrew from the study. There were no significant differences in clinical scores, age or sex between the group of patients that did the follow-up assessment and the group of patients that did not.

2.2. Seizure therapy {#s0020}
--------------------

ECT was administered with spectrum 500Q (MECTA Corporation) according to standards of practice ([@bb0335]). Of the 22 patients who completed ECT treatment, 14 patients received right unilateral ultra-brief (RUL-UB) pulse width ECT, 2 received bitemporal brief pulse (BL) ECT and the rest (6 patients) started on RUL-UB and then switched to BL ECT due to the lack of efficacy. Treatments were administered 2--3 times a week and continued until patients were in remission or improvement plateaued. MST was administered using the MagPro MST using a Twin Coil (MagVenture). The centre of each circular coil was placed over F3 and F4 respectively, using the international 10--20 system for EEG electrode placement. The highest electric field strength roughly corresponds to Fz ([@bb0075]) or the dorsomedial prefrontal cortex. Of the 24 patients who received MST, 12 patients received 100 Hz MST, 1 patient received 60 Hz, 2 received 50 Hz and 9 received 25 Hz. Treatments were administered 2--3 times per week until remission or up to a maximum of 24 sessions. Please see [Table 1](#t0005){ref-type="table"} for additional details.Table 1Clinical data table.Table 1TRD*n*ECT Pre + Post*n*MST Pre + Post*n*Demographic Characteristics Age, years: mean (std)45.7 (14.4)7546.8 (15.8)2242.0 (13.4)24 Sex, M/F31/44758/142212/1224Clinical Characteristics Illness Duration: mean (std)20.3 (13.2)7419.0 (12.0)2220.3 (13.7)24 On Medications (Antidepressants or Benzodiazepines) (Yes/No)60/107020/22220/424 Avg. No. of Treatment Sessions: mean (std)----14.2 (5.2)2220.2 (6.19)24 Site of Treatment [a](#tf0005){ref-type="table-fn"}----RUL UB14DMPFC24RUL UB then BL6BL2 Stimulation Frequency: [a](#tf0005){ref-type="table-fn"}--------100 Hz1260 Hz150 Hz225 Hz9Clinical Assessments HRSD, % change following Seizure Therapy: mean (std)36.7 (30.0)4644.8 (28.6)2229.3 (29.9)24 Initial HRSD scores, mean(std)26.6 (4.44)7424.5 (3.81)2228.1 (4.73)24 Post HRSD scores, mean(std)----13.0 (6.19)2219.3 (7.96)24 HRSD, Responders/Nonresponders [b](#tf0010){ref-type="table-fn"}20/264613/9227/1724 MoCA, change following seizure therapy: mean (std)0.56 (3.32)46--3 (2.97)61.57 (2.69)21 MoCA: \# patients with improvement \> 01227061221 BDI, % change: mean (std)----49.2 (31.2)17---- BDI, Responders/Nonresponders [b](#tf0010){ref-type="table-fn"}----9/817---- MADRS, % change: mean (std)----50.0 (32.6)18---- MADRS, Responders, Nonresponders [b](#tf0010){ref-type="table-fn"}----11/718---- SSI, change: mean (std)--------6.4 (6.4)20 SSI, Responders/Nonresponders [b](#tf0010){ref-type="table-fn"}--------16/420[^1][^2][^3]

2.3. Clinical assessments {#s0025}
-------------------------

Prior to and following a course of ECT, the 17-scale Hamilton Rating Scale for Depression (HRSD) and Montreal Cognitive Assessment (MoCA) v7.1--7.3 were used to clinically assess severity of depression and global cognition. Montgomery-Åsberg Depression Rating Scale (MADRS) and Beck\'s Depression Inventory (BDI-II) scale were also used to assess clinical severity of depression and self-rated depression symptoms, respectively. Prior to and following a course of MST, the 24-scale HRSD and Montreal Cognitive Assessment (MoCA) v7.1--7.3 were used to clinically assess severity of depression and global cognition. Severity of suicidal thoughts and overall risk for suicide was assessed using the Scale for Suicidal Ideation (SSI). For all SSI-related analyses, only participants who showed suicidal ideation at baseline were included. The criterion for treatment response was a minimum of 50% improvement in HRSD (final scores were \<17). Response for BDI, MADRS and SSI was also defined as a minimum of 50% improvement in score. Demographic and clinical characteristics are presented in [Table 1](#t0005){ref-type="table"}.

2.4. Data recording and pre-processing {#s0030}
--------------------------------------

Eyes-closed rest EEG data was collected within a week prior to the first treatment session and again within 2 weeks after the completion of the last treatment. Data was recorded with the Compumedics (Charlotte, NC, USA) Neuroscan SynAmps 2/RT 64-channel EEG system at 10 kHz. During pre-processing, EEG data was downsampled to 1000 Hz, divided into 2-s epochs, bandpass-filtered between 1 and 80 Hz, and notch-filtered at 60 Hz. With the removal of eye electrodes and other unused channels, the total number of EEG channels used for analysis was 60. Using EEGLAB ([@bb0065]), independent component analysis was used to extract eye, muscle and electrode artifacts. Deleted EEG channels were interpolated using spherical spline interpolation ([@bb0300]) and data was re-referenced to an average reference. This preprocessing pipeline is currently made available as ERPEEG (<http://www.tmseeg.com/multisiteprojects/>). Channels were deleted if: (i) they were disconnected during collection for a significant amount of the data collection time (\>40%), or (ii) heavily contaminated with noise (muscle or spurious artifacts) for a significant part of the data collection time (\>40%). On average, 6 ± 3 independent components were removed and 3 ± 1 channels were deleted and interpolated in the data collected from healthy subjects. In the data collected from patients at baseline, 9 ± 5 independent components were removed and 3 ± 1 channels were deleted and interpolated. In the data collected from patients following treatment, 10 ± 5 independent components were removed and 3 ± 2 channels were deleted and interpolated.

2.5. Microstate analysis {#s0035}
------------------------

Microstate analysis followed the standard procedure outlined in seminal work (Fig. S1) ([@bb0220]; [@bb0285]) and was implemented using CARTOOL ([@bb0035]). Prior to the application of microstate analysis, four minutes of the pre-processed EEG data was bandpass-filtered from 1 to 30 Hz.

Global field power is a measure of the electric field strength over the scalp and is defined as the variance in electrical activity across EEG electrodes at each time point (Eq. [(1)](#fo0005){ref-type="disp-formula"}). The topographical maps at the local maxima peaks of the global field power curve are clustered to derive the four prototypical microstate classes ([@bb0210]). Using a data-driven approach, the optimal number of clusters for the data used in this study was found to be four (Fig. S2).$$\mathit{GFP}\left( t \right) = \sqrt{\frac{\left\lbrack {\sum\limits_{i}^{N}\left( {V_{i}\left( t \right) - V_{\mathit{mean}}\left( t \right)} \right)} \right\rbrack^{2}}{N}}$$where N represents the number of EEG electrodes (*i* = 1:60 electrodes) and *v* represents the electrical potential measured over the scalp. In addition, *v*~*i*~ represents the electrical potential measured at electrode (*i*) and time (*t*), and *v*~*mean*~ represents the average electrical potential over all electrodes at time (*t*).

In this study, the topographical atomize--agglomerate hierarchical clustering algorithm([@bb0375]) was applied across all subjects and conditions (global approach). By recalculating microstate classes for each subject or condition, minor differences may be introduced in the microstate topographies. The global clustering approach provides low within-subject error and high test-retest reliability in resting-state microstate analysis ([@bb0190]). Clustered microstates were labelled A, B, C and D as seen in seminal work ([@bb0210]) and explained 83% of variance in our data. In the final step, topographical maps at each local maxima point of the global field power curve were assigned to the microstate class of highest correlation using spatial Pearson\'s product-moment correlation coefficient (Eq. [(2)](#fo0010){ref-type="disp-formula"}) ([@bb0020]). Three features were calculated for each of the four microstate classes: (i) average duration, (ii) frequency, and (iii) coverage. Average duration is the amount of time a microstate class remains stable when it appears, in milliseconds; frequency refers to the occurrence of each microstate class per second; and coverage is the percent of recording covered by each microstate class.$$r_{\mathit{spatial}} = 1 - \frac{1}{2}\ \left\lbrack {\frac{1}{N}\sum\limits_{i = 1}^{N}\left\{ {\frac{u_{i} - u_{\mathit{mean}}}{\sqrt{\sum\limits_{i = 1}^{N}\left( {u_{i} - u_{\mathit{mean}}} \right)^{2}/N}} - \frac{v_{i} - v_{\mathit{mean}}}{\sqrt{\sum\limits_{i = 1}^{N}\left( {v_{i} - v_{\mathit{mean}}} \right)^{2}/N}}} \right\}^{2}} \right\rbrack\ $$where N represents the number of EEG electrodes (*i* = 1:60 electrodes) and *u* and *v* represent the 2 different spatial topographies (maps) being correlated. In addition, *u*~*i*~*, v*~*i*~ represent the electrical potential measured at electrode *i* of the 2 maps and *u*~*mean*~, *v*~*mean*~ represent the average electric potential over all electrodes.

2.6. Statistical analysis {#s0040}
-------------------------

To examine the effect of treatment response (≥50% improvement in HRSD) on microstate characteristics following seizure therapy (ECT and MST), a 2 × 2 × 4 repeated-measures ANOVA ([@bb0225]; [@bb0380]) was conducted for each microstate feature (Duration, Frequency and Coverage) with *RESPONSE* (Responder, Non-responder) as a categorical factor, and *TIME* (Pre, Post) and *MICROSTATE CLASS* (A, B, C, D) as the repeated-measures factors. These ANOVAs were performed on the ECT and MST group data separately as well.

For each microstate feature (Duration, Frequency and Coverage), a 2 × 4 repeated-measured ANCOVA ([@bb0225]; [@bb0380]) was conducted between (2 *GROUPS*) healthy controls and patients with treatment-resistant depression prior to seizure therapy using *MICROSTATE CLASS* (A, B, C and D) as the repeated-measure. For each of the three microstate features, an ANCOVA was performed again between (2 *GROUPS)* healthy controls and patients following seizure therapy using *MICROSTATE CLASS* (A, B, C and D) as the repeated-measure. Age was used as a covariate. There were no significant effects of gender.

Based on our hypothesis that seizure therapy modulates global neural dynamics, planned comparisons were performed to determine whether changes in microstate characteristics were associated with treatment response. For each of the three microstate characteristics (duration, frequency, coverage), paired *t*-tests were performed to compare the characteristic before and after treatment for each of the four states. The results were corrected for multiple comparisons using the Bonferroni correction method (for the 4 microstates).

A significance level of α \< 0.05 was used for all statistical tests. Pairwise post-hoc comparisons were performed using Tukey-HSD. All planned comparisons were corrected using the Bonferroni method (4 comparisons for the 4 microstate classes).

2.7. Correlation and predictive analysis {#s0045}
----------------------------------------

Associations between microstate characteristics and clinical assessments (HRSD, MADRS, BDI, MoCA, SSI) were evaluated with a non-parametric spearman rank-order correlation test and corrected for multiple-comparisons using permutation tests. Receiver operating characteristic (ROC) curves were used to assess predictive value of significant spearman rank-order correlations (i.e., correlations with *p* \< 0.05). Significance of prediction for the ROC curves was quantified through area under the curve (AUC). Only AUC values greater than or equal to 0.7 (i.e., fair, good or excellent predictors) are reported in this manuscript. For ROC curves with HRSD, MADRS or BDI, subjects were grouped to be responders (≥ 50% improvement in symptoms) or non-responders. For ROC curves with MoCA, subjects were grouped to have cognitive decline if the percent change in MoCA was negative.

Microstate features were correlated with the percent change in clinical scores following therapy. Raw clinical scores (e.g., HRSD) were not used for correlation analysis. Change in microstate features was calculated as (Post-Pre)/Pre\*100 where a higher percentage represents an increase in the feature value; change in HRSD, MADRS and BDI were calculated as (Pre-Post)/Pre\*100 where a higher percentage represents improvement in depressive symptoms; and lastly change in MoCA and SSI were calculated as (Post-Pre) where a higher value represents improvement in cognition or suicidal ideation symptoms.

2.8. Source localization {#s0050}
------------------------

The eLORETA algorithm was used to localize the four global-clustered microstates in the source domain. Using LORETA-KEY ([@bb0290]), the co-ordinates of the 60 electrodes were identified according to the 10--10 system. A transformation matrix (60 × 6239) was then derived with a relative regularization parameter of 1.

2.9. Power spectral density analysis {#s0055}
------------------------------------

The EEGLAB function *spectopo* was used to obtain the power spectrum for each electrode. Relative power was obtained for 1 to 30 Hz (to be consistent with microstate analysis) and was calculated as the ratio of the power at each frequency relative to the sum of power across all frequencies. In addition, relative power was calculated as an average over the following bands: Delta: 1--4 Hz; Theta: 4--8 Hz; Alpha: 8--14 Hz; Low Beta: 14--20 Hz; High Beta: 20--30 Hz. Spearman rank-order correlations were performed between power in each band and the characteristics of microstate analysis (duration, frequency and coverage). The results are reported as a correlation matrix. Correlation *p*-values were also calculated and were Bonferroni-corrected for multiple comparisons (12 comparisons: 4 microstate classes by 3 features).

3. Results {#s0060}
==========

A significant improvement in HRSD score was observed following ECT (paired *t* = −6.6; *df* = 21; *p* \< 0.0001; Cohen\'s *d* = 2.2), following MST (paired *t* = −4.62, *df* = 23; *p* = 0.0001; Cohen\'s *d* = 1.3) and when both the groups were combined as seizure therapy (paired *t* = −7.8, *df* = 45; *p* \< 0.0001; Cohen\'s *d* = 1.6). In addition, there was a significant improvement in BDI score (paired *t* = −5.8, *df* = 16; *p* \< 0.0001; Cohen\'s *d* = 1.9) and a decrease in MoCA score (cognition) approaching significance (paired *t* = −2.5; *df* = 5; *p* = 0.05; Cohen\'s *d* = 1.2) following ECT. Suicidal ideation (paired *t* = −4.5, *df* = 19; *p* = 0.0002; Cohen\'s *d* = 1.3) and cognition scores (paired *t* = 2.7, *df* = 20; *p* = 0.01; Cohen\'s *d* = 0.48) significantly changed following MST.

3.1. Effect of seizure therapy on EEG microstate dynamics {#s0065}
---------------------------------------------------------

### 3.1.1. Seizure therapy (ECT and MST) {#s0070}

A main effect of *Time* (F = 15.9; *df* = 1,44; *p* = 0.0003; ƞ~p~^2^ = 0.27) and *Microstate Class* (F = 13.2; *df* = 3,132; *p* \< 0.0001; ƞ~p~^2^ = 0.23) were observed in the duration of microstates. The interaction of *Time* × *Microstate Class* was not significant (F = 1.2; *df* = 3,132; *p* = 0.3; ƞ~p~^2^ = 0.026). An effect of *response* (≥50% improvement in HRSD) was not observed (F = 0.57; *df* = 1,44; *p* = 0.5; ƞ~p~^2^ = 0.013). Since all the states increased in duration following seizure therapy (ranging between 3.3 to 8.2 ms), paired *t*-tests were performed to identify which states revealed a statistically significant increase in duration. These were corrected using the Bonferroni method for 4 comparisons (4 microstates). State A (paired *t* = 5.0; *df* = 45; *Bonferroni-corrected p* \< 0.0001; Cohen\'s *d* = 0.77) showed a significant increase in duration following seizure therapy (left panel of [Fig. 1](#f0005){ref-type="fig"}A). There was no significant change in the duration of State B (paired *t* = 2.4; *df* = 45; *Bonferroni-corrected p* = 0.08; Cohen\'s *d* = 0.33), State C (paired *t* = 2.2; *df* = 45; *Bonferroni-corrected p* = 0.1; Cohen\'s *d* = 0.32), or State D (paired *t* = 1.4; *df* = 45; *Bonferroni-corrected p* = 0.7; Cohen\'s *d* = 0.15) (left panels of [Fig. 1](#f0005){ref-type="fig"}B--D).Fig. 1**Effect of seizure therapy (ECT and MST) on the average duration of all four microstates.** In each subplot, the raw data is plotted on top of a boxplot showing the mean (red line), 95% confidence interval (red area) and 1 standard deviation (blue area). Significant comparisons are marked with a green (\*). **(A) Left panel:** Following seizure therapy (ECT and MST), there was a significant increase in the duration of State A (y-axis) (*p* \< 0.0001). **Middle and right panels:** This increase was specific to responders of seizure therapy (*p* \< 0.0001). **(B)** No significant changes were observed in the duration of State B. **(C)** No significant changes were observed in the duration of State C. **(D)** No significant changes were observed in the duration of State D.Fig. 1

A main effect of *Time* (F = 12.4; *df* = 1,44; *p* = 0.001; ƞ~p~^2^ = 0.22) and *Microstate Class* (F = 3.5; *df* = 3,132; *p* = 0.02; ƞ~p~^2^ = 0.07) was observed in the frequency of microstates. The interaction of *Time* × *Microstate Class* approached significance (F = 2.4; *df* = 3,132; *p* = 0.06; ƞ~p~^2^ = 0.052). Post-hoc Tukey-HSD tests revealed that State B (HSD = 4.7; *df* = 132; *p* *=* 0.03; Cohen\'s *d* = 0.65) (left panel of [Fig. 2](#f0010){ref-type="fig"}B), State C (HSD = 5.6; *df* = 132; *p* *=* 0.004; Cohen\'s *d* = 0.78) (left panel of [Fig. 2](#f0010){ref-type="fig"}C) and State D (HSD = 6.2; *df* = 132; *p* *=* 0.0008; Cohen\'s *d* = 0.87) (left panel of [Fig. 2](#f0010){ref-type="fig"}D) *significantly* decreased in frequency following seizure therapy. There was no significant change in the frequency of State A (HSD = 1.3; *df* = 132; *p* = 0.99; Cohen\'s *d* = 0.19) (left panel of [Fig. 2](#f0010){ref-type="fig"}A). An effect of *response* was not observed (F = 0.54; *df* = 1,44; *p* = 0.5; ƞ~p~^2^ = 0.012).Fig. 2**Effect of seizure therapy (ECT and MST) on the frequency of all four microstates.** In each subplot, the raw data is plotted on top of a boxplot showing the mean (red line), 95% confidence interval (red area) and 1 standard deviation (blue area). Significant comparisons are marked with a green (\*). **(A)** No significant changes were observed in the frequency of State A. **(B) Left panel:** A decrease in the frequency of State B (y-axis) was observed following seizure therapy (*p* = 0.03). **Middle and right panels:** This decrease in frequency of State B was specific to responders of seizure therapy (*p* = 0.01). **(C) Left panel:** A decrease in the frequency of State C (y-axis) was observed following seizure therapy (*p* = 0.004). **Middle and right panels:** This decrease in frequency of State C was specific to responders of seizure therapy (*p* = 0.0004). **(D) Left panel:** A decrease in the frequency of State D (y-axis) was observed following seizure therapy (*p* = 0.0008). **Middle and right panels:** This decrease in frequency of State D was specific to responders of seizure therapy (*p* = 0.04).Fig. 2

Apart from the main effect of *Microstate Class* (F = 8.6; *df* = 3,132; *p* \< 0.0001; ƞ~p~^2^ = 0.16), no significant effects were observed in the coverage of microstates (Fig. S3).

Planned comparisons were conducted to investigate the effect of response based on our hypotheses. The increase in State A duration was specific to responders of seizure therapy (*t* = 6.3; *df* = 19; *p* \< 0.0001; Bonferroni-corrected *p* \< 0.0001; Cohen\'s *d* = 1.1) (middle panel of [Fig. 1](#f0005){ref-type="fig"}A). This effect was not observed in non-responders for State A (*t* = 2.2; *df* = 25; *p* = 0.03; Bonferroni-corrected *p* = 0.1; Cohen\'s *d* = 0.48) (right panel of [Fig. 1](#f0005){ref-type="fig"}A). The decrease in frequency of State B (*t* = −3.3; *df* = 19; *p* = 0.004; Bonferroni-corrected *p* = 0.01; Cohen\'s *d* = 0.56), State C (*t* = −4.9; *df* = 19; *p* = 0.0001; Bonferroni-corrected *p* = 0.0004; Cohen\'s *d* = 0.80) and State D (*t* = −2.8; *df* = 19; *p* = 0.01; Bonferroni-corrected *p* = 0.04; Cohen\'s *d* = 0.53) was specific to responders of seizure therapy (middle panels of [Fig. 2](#f0010){ref-type="fig"}B--D). This effect was not observed in non-responders for State B (*t* = −1.1; *df* = 25; *p* = 0.3; Cohen\'s *d* = 0.15), State C (*t* = −1.3; *df* = 25; *p* = 0.19; Cohen\'s *d* = 0.31) or State D (*t* = −1.5; *df* = 25; *p* = 0.2; Cohen\'s *d* = 0.28) (right panels of [Fig. 2](#f0010){ref-type="fig"}B--D).

### 3.1.2. Electroconvulsive therapy {#s0075}

A main effect of *Time* (F = 8.3; *df* = 1,20; *p* = 0.009; ƞ~p~^2^ = 0.29) and *Microstate Class* (F = 5.9; *df* = 3,60; *p* = 0.001; ƞ~p~^2^ = 0.23) was observed in the duration of microstates. The interaction of *Time* × *Microstate Class* was not significant (F = 0.71; *df* = 3,60; *p* = 0.6; ƞ~p~^2^ = 0.034). An effect of *response* was not observed (F = 0.002; *df* = 1,20; *p* = 0.97; ƞ~p~^2^ = 0.00008). Since all the states increased in duration following ECT (ranging between 6.1 to 11.1 ms), paired *t*-tests were performed to identify which states revealed a statistically significant increase in duration. These were corrected using the Bonferroni method for 4 comparisons (4 microstates). State A (paired *t* = 5.7; *df* = 21; *Bonferroni-corrected p* \< 0.0001; Cohen\'s *d* = 1.08) showed a significant increase in duration following ECT (left panel of [Fig. 3](#f0015){ref-type="fig"}A). There was no significant change in the duration of State B (paired *t* = 1.7; *df* = 21; *Bonferroni-corrected p* = 0.4; Cohen\'s *d* = 0.36), State C (paired t = 1.7; *df* = 21; *Bonferroni-corrected p* = 0.4; Cohen\'s *d* = 0.43) or State D (paired *t* = 2.3; *df* = 21; *Bonferroni-corrected p* = 0.1; Cohen\'s *d* = 0.35) (left panels of [Fig. 3](#f0015){ref-type="fig"}B--D).Fig. 3**Effect of electroconvulsive therapy (ECT) on the average duration of all four microstates.** In each subplot, the raw data is plotted on top of a boxplot showing the mean (red line), 95% confidence interval (red area) and 1 standard deviation (blue area). Significant comparisons are marked with a green (\*). **(A) Left panel:** Following ECT, there was a significant increase in the duration of State A (y-axis) (*p* \< 0.0001). **Middle panel and right:** This increase was specific to responders of ECT (*p* \< 0.0001). **(B)** No significant changes were observed in the duration of State B. **(C)** No significant changes were observed in the duration of State C. **(D)** No significant changes were observed in the duration of State D.Fig. 3

A main effect of *Time* (F = 7.3; *df* = 1,20; *p* = 0.01; ƞ~p~^2^ = 0.27), and an interaction effect of *Time* × *Microstate Class* (F = 3.4; *df* = 3,60; *p* = 0.02; ƞ~p~^2^ = 0.15) were observed in the frequency of microstates. The main effect of *Microstate Class* was not significant (F = 1.3; *df* = 3,60; *p* = 0.3; ƞ~p~^2^ = 0.06). All states decreased in frequency following ECT. Post-hoc Tukey-HSD tests revealed that State B (HSD = 4.4; *df* = 60; *p* *=* 0.03; Cohen\'s *d* = 1.0) (left panel of [Fig. 4](#f0020){ref-type="fig"}B), State C (HSD = 5.7; *df* = 60; *p* *=* 0.002; Cohen\'s *d* = 1.24) (left panel of [Fig. 4](#f0020){ref-type="fig"}C) and State D (HSD = 6.6; *df* = 60; *p* *=* 0.0003; Cohen\'s *d* = 1.46) (left panel of [Fig. 4](#f0020){ref-type="fig"}D) *significantly* decreased in frequency following ECT. There was no significant change in the frequency of State A (HSD = 0.54; *df* = 60; *p* = 0.99; Cohen\'s *d* = 0.11) (left panel of [Fig. 4](#f0020){ref-type="fig"}A). An effect of *response* was not observed (F = 0.04; *df* = 1,20; *p* = 0.8; ƞ~p~^2^ = 0.002).Fig. 4**Effect of electroconvulsive therapy (ECT) on the frequency of all four microstates.** In each subplot, the raw data is plotted on top of a boxplot showing the mean (red line), 95% confidence interval (red area) and 1 standard deviation (blue area). Significant comparisons are marked with a green (\*). **(A)** No significant changes were observed in the frequency of State A. **(B) Left panel:** A decrease in the frequency of State B (y-axis) was observed following ECT (*p* = 0.03). **Middle and right panels:** This decrease in frequency of State B was specific to responders of ECT (*p* = 0.03). **(C) Left panel:** A decrease in the frequency of State C (y-axis) was observed following ECT (*p* = 0.002). **Middle and right panels:** This decrease in frequency of State C was specific to responders of ECT (*p* = 0.008). **(D) Left panel:** A decrease in the frequency of State D (y-axis) was observed following ECT (*p* = 0.0003). **Middle and right panels:** This decrease in frequency of State D was specific to responders of ECT (*p* = 0.04).Fig. 4

Apart from the main effect of *Microstate Class* (F = 3.1; *df* = 3,60; *p* = 0.03; ƞ~p~^2^ = 0.13), no significant effects were observed in the coverage of microstates (Fig. S4).

Planned comparisons revealed that the increase in State A duration was specific to responders of ECT (*t* = 8.5; *df* = 12; *p* \< 0.0001; Bonferroni-corrected *p* \< 0.0001; Cohen\'s *d* = 1.60) (middle panel of [Fig. 3](#f0015){ref-type="fig"}A). This effect was not observed in non-responders for State A (*t* = 1.7; *df* = 8; *p* = 0.1; Cohen\'s *d* = 0.52) (right panel of [Fig. 3](#f0015){ref-type="fig"}A). A decrease in the frequency of State B (*t* = −3.1; *df* = 12; *p* = 0.008; Bonferroni-corrected *p* = 0.03; Cohen\'s *d* = 0.67) (middle panel of [Fig. 4](#f0020){ref-type="fig"}B), State C (*t* = −4.0; *df* = 12; *p* = 0.002; Bonferroni-corrected *p* = 0.008; Cohen\'s *d* = 0.90) (middle panel of [Fig. 4](#f0020){ref-type="fig"}C) and State D (*t* = −2.9; *df* = 12; *p* = 0.01; Bonferroni-corrected *p* = 0.04; Cohen\'s *d* = 0.71) (middle panel of [Fig. 4](#f0020){ref-type="fig"}D) was specific to responders of ECT. This effect was not observed in non-responders for State B (*t* = −0.78; *df* = 8; *p* = 0.5; Cohen\'s *d* = 0.24), State C (*t* = −2.0; *df* = 8; *p* = 0.08; Cohen\'s *d* = 0.67) or State D (*t* = −1.6; *df* = 8; *p* = 0.2; Cohen\'s *d* = 0.71) (right panels of [Fig. 4](#f0020){ref-type="fig"}B--D).

### 3.1.3. Magnetic seizure therapy {#s0080}

Similar to ECT, there was an increase in duration and decrease in frequency of microstates following MST. A main effect of *Time* (F = 6.8; *df* = 1,22; *p* = 0.01; ƞ~p~^2^ = 0.24) and *Microstate Class* (F = 6.4; *df* = 3,66; *p* = 0.0007; ƞ~p~^2^ = 0.23) was observed in the duration feature. The interaction effect of *Time* × *Microstate Class* was not significant (F = 0.11; *df* = 3,66; *p* = 0.96; ƞ~p~^2^ = 0.005). An effect of *response* was not observed (F = 2.3; *df* = 1,22; *p* = 0.2; ƞ~p~^2^ = 0.094). In addition, a main effect of *Time* (F = 4.4; *df* = 1,22; *p* = 0.04; ƞ~p~^2^ = 0.16) and a main effect of *Microstate Class* (F = 4.0; *df* = 3,66; *p* = 0.01; ƞ~p~^2^ = 0.15) were observed in the frequency feature. The interaction effect of *Time* × *Microstate Class* was not significant (F = 0.075; *df* = 3,66; *p* = 0.97; ƞ~p~^2^ = 0.003). An effect of *response* was not observed (F = 2.4; *df* = 1,22; *p* = 0.1; ƞ~p~^2^ = 0.10). Apart from the main effect of *Microstate Class* (F = 5.8; *df* = 3,66; *p* = 0.001; ƞ~p~^2^ = 0.21), no significant effects were observed in the coverage of microstates. See supplementary figures Fig. S5--S7. Planned comparisons were not significant (see supplementary Table 1).

3.2. Correlation and prediction analysis results {#s0085}
------------------------------------------------

### 3.2.1. Seizure therapy (ECT and MST) {#s0090}

An increase in the duration of State A correlated with improvement in depressive symptoms (HRSD) (*r* = 0.33, 95% CI 0.044 to 0.57, *p-corrected* = 0.02). The increase was also a fair predictor of improvement in depressive symptoms (HRSD) (AUC = 0.71, *p* = 0.003) ([Fig. 5](#f0025){ref-type="fig"}).Fig. 5**Change in the duration of State A following seizure therapy (ECT + MST) correlated with improvement in depressive symptoms (HRSD).** For the receiver operating characteristic (ROC) curve (right panels), the x-axes represents the false positive rate (1-specificity) and the y-axes represents the true positive rate (sensitivity). The red circle depicts the optimum operating point of the ROC curve. The area under the curve (AUC) at this optimum point is specified on the graph. **(A)** An increase in the duration of State A significantly correlated with improvement in depressive symptoms (x-axis), Hamilton Rating Scale for Depression (HRSD) (r = 0.33, *p* = 0.02). X-axis represents change in HRSD (pre-post)/(pre\*100). Y-axis represents change in coverage of State D (post-pre)/(pre\*100). **(B)** Change in State A duration was also a fair predictor of response to seizure therapy (AUC = 0.71, *p* = 0.003).Fig. 5

### 3.2.2. Electroconvulsive therapy {#s0095}

A decrease in State D duration following ECT treatment significantly correlated with improvement in self-rated depressive symptoms (BDI) (*r* = −0.55, 95% CI −0.82 to −0.09, *p-corrected* = 0.02) (left panel of [Fig. 6](#f0030){ref-type="fig"}B). The decrease was also a good predictor of improvement in self-rated depressive symptoms (BDI) (AUC = 0.83, *p* = 0.0007) (right panel of [Fig. 6](#f0030){ref-type="fig"}B). Based on the association of State C to the salience and State D to the frontoparietal network ([@bb0025]) and based on research indicating that the salience network facilitates the activation of the frontoparietal network ([@bb0245]), we hypothesized that the change in State D duration relative to the change in State C duration will also significantly correlate with clinical outcome. The log ratio between change in State D duration and change in State C duration correlated with improvement in self-rated depressive symptoms (BDI) (*r* = −0.67, 95% CI −0.87 to −0.28, *p* = 0.003) (left panel of [Fig. 6](#f0030){ref-type="fig"}C) and clinical depression scores (MADRS) (*r* = −0.50, 95% CI −0.78 to −0.04, *p* = 0.03). The ratio was also an excellent predictor of improvement in self-rated depressive symptoms (BDI) (AUC = 0.97, *p* \< 0.0001) (right panel of [Fig. 6](#f0030){ref-type="fig"}C).Fig. 6**Changes in microstate characteristics following electroconvulsive therapy (ECT) correlated with improvement in self-rated depressive symptoms.** For the receiver operating characteristic (ROC) curves (all right panels), the x-axes represents the false positive rate (1-specificity) and the y-axes represents the true positive rate (sensitivity). The red circle depicts the optimum operating point of the ROC curve. The area under the curve (AUC) at this optimum point is specified on the graph. **(A) Left panel:** An increase in the coverage of State A significantly correlated with improvement in self-rated depressive symptoms (x-axis), Beck\'s Depression Inventory scale (BDI) (r = 0.57, *p* = 0.02). X-axis represents change in BDI (pre-post)/(pre\*100). Y-axis represents change in coverage of State D (post-pre)/(pre\*100). **Right panel:** Change in State A coverage was also a strong predictor of response to ECT (BDI) (AUC = 0.79, *p* = 0.005). **(B) Left panel:** A decrease in the duration of State D was significantly correlated with improvement in BDI (*r* =−0.55, *p* = 0.02). X-axis represents change in BDI (pre-post)/(pre\*100). Y-axis represents change in duration of State D (post-pre)/(pre\*100). **Right panel:** Change in State D duration was also a strong predictor of response to ECT (BDI) (AUC = 0.83, *p* = 0.0007). **(C) Left panel:** The correlation between State D duration and BDI remained significant when the change in duration of State D was presented relative to the change in duration of State C (*r* = −0.66, *p* = 0.003). X-axis represents change in BDI (pre-post)/(pre\*100). Y-axis represents the log of the absolute ratio between change in duration of State D (post-pre)/(pre\*100) over the change in duration of State C (post-pre)/(pre\*100). **Right panel:** Ratio of change in State D duration over the change in State C duration was an excellent predictor of self-rated response to ECT (BDI) (AUC = 0.97, *p* \< 0.0001).Fig. 6

Furthermore, an increase in State A coverage correlated with improvement in self-rated depressive symptoms (BDI) (*r* = 0.57, 95% CI 0.12 to 0.82, *p-corrected* = 0.02) (left panel of [Fig. 6](#f0030){ref-type="fig"}A). The increase was also a fair predictor of improvement in self-rated depressive symptoms (BDI) (AUC = 0.79, *p* = 0.005) (right panel of [Fig. 6](#f0030){ref-type="fig"}A).

### 3.2.3. Magnetic seizure therapy {#s0100}

Changes in microstate dynamics following MST were not associated with change in depressive symptoms (see supplementary Table 2). Baseline characteristics of all microstates were shown to predict suicidal ideation response (right panels of [Fig. 7](#f0035){ref-type="fig"}A). At baseline, a shorter duration of State A (*r* = −0.57, 95% CI −0.81 to −0.17, *p-corrected* = 0.01), State B (*r* = −0.49, 95% CI −0.77 to −0.06, *p-corrected* = 0.03), State C (r = −0.49, 95% CI −0.77 to −0.06, *p-corrected* = 0.03) and a higher frequency of State D (*r* = 0.52, 95% CI 0.10 to 0.78, *p-corrected* = 0.02) predicted suicidal ideation response. Furthermore, a decrease in State B frequency was shown to be correlated with improvement in cognition (*r* = −0.50, 95% CI −0.77 to −0.09, *p-corrected* = 0.01) (middle panel of [Fig. 7](#f0035){ref-type="fig"}B) and was a good predictor of improvement in cognition (AUC = 0.80, *p* = 0.002) (right panel of [Fig. 7](#f0035){ref-type="fig"}B).Fig. 7**Effect of magnetic seizure therapy (MST) on microstate characteristics. (A) Left panel:** Following MST, patients showed a significant improvement in scale for suicidal ideation (SSI). **Middle and right panels:** Reduction in SSI was significantly associated with baseline resting-state microstate characteristics of all microstate classes. X-axes represents change in SSI score (Post-Pre) and y-axes represents baseline characteristics of each microstate A, B, C and D. **(B) Left panel:** Following MST, patients showed a significant improvement in cognition scores (Montreal Cognitive Assessment (MOCA)). **Middle panel:** A decrease in the frequency of State B following MST correlated with improvement in cognition scores. X-axis represents change in MOCA (Post-Pre) and y-axis represent change in State B frequency (post-pre)/(pre\*100). **Right panel:** This decrease in frequency was also a strong predictor of cognitive score outcome. The x-axis represents the false positive rate (1-specificity) and the y-axis represents the true positive rate (sensitivity). The red circle depicts the optimum operating point of the receiver operating characteristic curve. The area under curve (AUC) at this optimum point is specified on the graph (AUC = 0.80, *p* = 0.002).Fig. 7

3.3. Microstate dynamics in patients with treatment-resistant depression vs healthy controls {#s0105}
--------------------------------------------------------------------------------------------

Patients revealed an increased duration and decreased frequency of microstates compared to healthy subjects (left panels of [Fig. 8](#f0040){ref-type="fig"}A and [Fig. 8](#f0040){ref-type="fig"}C). By comparing healthy subjects with patients before treatment, a significant main effect of *Group* (F = 4.9; *df* = 1,127; *p* = 0.03; ƞ~p~^2^ = 0.04), *Microstate Class* (F = 12.2; *df* = 3,381; *p* \< 0.0001; ƞ~p~^2^ = 0.09) and an interaction effect of *Group* × *Microstate Class* approaching significance (F = 2.1; *df* = 3,381; *p* = 0.09; ƞ~p~^2^ = 0.02) was observed in the duration of microstates. A main effect of *Group* (F = 4.4; *df* = 1,127; *p* = 0.03; ƞ~p~^2^ = 0.03), *Microstate Class* (F = 7.6; *df* = 3,381; *p* = 0.01; ƞ~p~^2^ = 0.06) and an interaction effect of *Group* × *Microstate Class* (F = 3.8; *df* = 3,381; *p* = 0.01; ƞ~p~^2^ = 0.03) was observed in the frequency of microstates.Fig. 8**Microstate characteristics of treatment-resistant depression (TRD) compared to healthy (HLT) subjects before and after seizure therapy.** In each subplot, the raw data is plotted on top of a boxplot showing the mean (red line), 95% confidence interval (red area) and 1 standard deviation (blue area). All comparisons shown in **(A)** to **(D)** were significant. **(A) & (B)** Patients showed a longer duration (*p* = 0.03) and lower frequency (*p* = 0.03) of microstate dynamics compared to healthy subjects. **(C) & (D)** Following seizure therapy, patients showed a much longer duration (*p* \< 0.0001) and lower frequency (*p* = 0.0001) of microstates compared to healthy subjects. In all plots of (**A--D**, x-axes represents the subject group. In **(A--B)**, y-axis represents the duration of all microstates in milliseconds (main effect of group in ANCOVA). In **(C--D)**, y-axis represents the frequency of all microstates per second (main effect of group in ANCOVA). **(E)** Seizure therapy (ECT and MST) was shown to normalize the high coverage of State D in patients compared to healthy subjects (*p* = 0.01). X-axis represents each microstate class. Y-axis represents the percent coverage of all microstates, and each line in the graph represents a subject group (interaction effect of M*icrostate Class* × *Group* in ANCOVA).Fig. 8

A significant main effect of *Microstate Class* (F = 1.0; *df* = 3,381; *p* \< 0.0001; ƞ~p~^2^ = 0.08) and a significant interaction of *Group* × *Microstate Class* (F = 3.5; *df* = 3,381; *p* = 0.01; ƞ~p~^2^ = 0.03) was observed with the coverage feature between healthy subjects and patients at baseline ([Fig. 8](#f0040){ref-type="fig"}E). The main effect of *Group* was not significant (F = 2.1; *df* = 1,127; *p* = 0.2; ƞ~p~^2^ = 0.02).

3.4. Microstate dynamics in patients with treatment-resistant depression following seizure therapy vs healthy controls {#s0110}
----------------------------------------------------------------------------------------------------------------------

The longer duration and lower frequency of microstates in patients persisted following treatment ([Fig. 8](#f0040){ref-type="fig"}B and D). Comparing healthy subjects with patients after seizure therapy, there was a main effect of *Group* (F = 19.4; *df* = 1,98; *p* \< 0.0001; ƞ~p~^2^ = 0.17) and *Microstate Class* (F = 12.1; *df* = 3,294; *p* \< 0.0001; ƞ~p~^2^ = 0.11) in the duration feature. The interaction of *Group* × *Microstate Class* was not significant (F = 1.1; *df* = 3,294; *p* = 0.36; ƞ~p~^2^ = 0.01). In the frequency feature, there was a significant main effect of *Group* (F = 16.3; *df* = 1,98; *p* = 0.0001; ƞ~p~^2^ = 0.14) and *Microstate Class* (F = 6.1; *df* = 3,294; *p* = 0.0005; ƞ~p~^2^ = 0.06). The interaction of *Group* × *Microstate Class* was not significant (F = 1.5; *df* = 3,294; *p* = 0.22; ƞ~p~^2^ = 0.02).

The main effect of *Microstate Class* was significant in the coverage feature (F = 8.8; *df* = 3,294; *p* \< 0.0001; ƞ~p~^2^ = 0.08). The main effect of Group (F = 1.4; *df* = 1,98; *p* = 0.24; ƞ~p~^2^ = 0.003) and the interaction effect of *Group × Microstate Class* (F = 1.2; *df* = 3,294; *p* = 0.32; ƞ~p~^2^ = 0.01) were not significant ([Fig. 8](#f0040){ref-type="fig"}E).

3.5. Source localization of the global-clustered microstates {#s0115}
------------------------------------------------------------

In [Fig. 9](#f0045){ref-type="fig"}, the global-clustered microstates are shown alongside their corresponding eLORETA images. All states show a common neural generator in the posterior cingulate and cingulate gyrus. This has been shown in previous literature ([@bb0295]). State A was associated with the left superior and middle temporal gyrus ([Fig. 9](#f0045){ref-type="fig"}A). State B with the cuneus and precuneus of the occipital lobe ([Fig. 9](#f0045){ref-type="fig"}B). State C was best associated with the anterior cingulate, insula and cuneus and precuneus of the occipital lobe ([Fig. 9](#f0045){ref-type="fig"}C). Finally, State D with the paracentral lobe of the frontal lobe, the precuneus of the parietal lobe, the parahippocampal gyrus of the limbic lobe, and the lingual gyrus of the occipital lobe ([Fig. 9](#f0045){ref-type="fig"}D). See Fig. S8-S11 for more detailed images of source localization.Fig. 9**Global microstate classes clustered over all groups and all subjects with their source (eLORETA) images.** All microstates show activation in the posterior cingulate gyrus. **(A)** Microstate A was shown to be associated with the left superior and middle temporal gyrus. **(B)** Microstate B was associated with the cuneus and precuneus of the occipital lobe. **(C)** Microstate C was associated with the anterior cingulate, insula and cuneus and precuneus of the occipital lobe. **(D)** Microstate D was associated with the paracentral lobe of the frontal lobe, the precuneus of the parietal lobe, the parahippocampal gyrus, and the lingual gyrus of the occipital lobe.Fig. 9

3.6. Power spectral density analysis {#s0120}
------------------------------------

### 3.6.1. Neuronal oscillations in patients vs healthy controls {#s0125}

No significant differences were observed in relative power between the healthy and patient groups after cluster-based permutation correction for multiple comparisons (Fig. S12).

### 3.6.2. Effect of seizure therapy on neuronal oscillations {#s0130}

Following cluster-based permutation correction, both ECT responders and non-responders revealed an increase in relative power of slow cortical oscillations (1--7 Hz) and a decrease in relative power of oscillations above 10 Hz (Fig. S13A--B). The increase in relative power of slow cortical oscillations was not observed in responders or non-responders of MST (Fig. S13C--D). Common to ECT and MST however, was a decrease in relative power above 17 Hz. In responders of MST, a decrease in relative power was observed above 17 Hz. In non-responders of MST, a decrease in relative power was observed above 11 Hz.

### 3.6.3. Microstate dynamics and neuronal oscillations {#s0135}

In the ECT group, the increase in slow oscillations was not correlated with microstate characteristics (Fig. S14). Only changes in the low beta and high beta power bands correlated with change in duration and frequency of microstates. A significant change in duration of microstates following ECT was specific to State A. However, changes in low beta and high beta were correlated with changes in duration of States B and C. Significant change in frequency of microstates following ECT was specific to States B, C and D. Yet, change in low beta correlated with change in frequency of States A and D and change in high beta correlated with change in frequency of States A, B and D. In the MST group, none of the power bands significantly correlated with microstate characteristics (Fig. S15).

4. Discussion {#s0140}
=============

This study presents the first evidence for the modulation of resting-state EEG microstate dynamics by seizure therapy in patients with treatment-resistant depression. First, several changes in microstate dynamics following seizure therapy suggested that ECT selectively modifies global brain network dynamics. An increase in the duration of State A and a decrease in the frequency of States B, C and D were associated with response to seizure therapy (specifically ECT). Although there was a change in network dynamics following MST, it was not network-specific and it was not specific to responders. However, a decrease in the frequency of State B was associated with improvement in cognition following MST. In addition, baseline microstate dynamics were shown to predict suicidal ideation response to MST (shorter duration of States A, B, C and a higher frequency of State D). Finally, patients revealed increased duration and decreased frequency of microstates compared to healthy subjects. Following seizure therapy, this difference was greater between patients and healthy subjects. Collectively, these findings provide insight into the role of global network dynamics in the potential mechanism of action of seizure therapy for treatment-resistant depression.

Although the most effective treatment for treatment-resistant depression is ECT, its underlying mechanism of action is not clearly understood. In this study, a significant increase in the duration of State A and decrease in the frequency of States B, C and D was observed in responders of seizure therapy (specifically ECT). We hypothesize that this might reflect a relative stabilization (or reduction) of microstate dynamics since it infers that the microstate occurs for a longer duration of time and is less variable (i.e., more stable). This finding may support one of the main theories on the efficacy of ECT, the anticonvulsant hypothesis ([@bb0050]; [@bb0325]). The anticonvulsant hypothesis suggests that an activation of inhibitory mechanisms initially occurs to inhibit seizures caused by ECT but eventually leads to the inhibition of hyperactive networks in depression, which may lead to reduced global network dynamics. There is a large amount of accumulating evidence for the anticonvulsant hypothesis, such as increased cortical GABA ([@bb0340]), decreased regional brain metabolism ([@bb0155]), increased slow-wave EEG activity as well as decreased seizure duration and increased seizure threshold over the course of ECT ([@bb0325]). The potential stabilization of microstate (i.e., global network) dynamics following seizure therapy further adds to this line of evidence.

In a recent comprehensive meta-analysis of resting-state fMRI studies ([@bb0170]), depression was associated with aberrant interactions between the salience, frontoparietal and default-mode networks, argued to be the facilitators of depressive symptoms. With recent progress in the integration of fMRI and EEG data, a few studies have explored the association between cortical microstate activity and resting-state fMRI networks ([@bb0275]; [@bb0350]; [@bb0165]). In *Britz* et al. *(*[@bb0025]*)*, the salience and frontoparietal networks were associated with States C and D. As hypothesized in this study, the frequency of States C and D decreased following seizure therapy and these changes were associated with treatment response (specifically ECT). In addition, change in State D duration relative to the change in State C duration correlated with improvement in depressive symptoms following ECT. This suggests that the interaction between the neural generators underlying these microstates may be impaired in patients with treatment-resistant depression, and may be linked to the role of State C as a dynamic "switching network". This role of State C has been widely postulated in schizophrenia-related microstate research ([@bb0310]).

As an alternate to ECT, MST was proposed to minimize cognitive side effects while maintaining antidepressant efficacy. A few studies have even associated MST with improvement in cognition including visual-spatial learning, memory and phonological tasks ([@bb0230]; [@bb0175]; [@bb0180]). The association between change in State B frequency and improvement in cognition with MST may be in line with these findings since State B has been associated with the parietal and occipital-parietal areas of spatial-visualization and verbalization ([@bb0025]; [@bb0260]). In addition to cognition, MST was previously associated with remission of suicidal ideation. Baseline markers of inhibitory neurotransmission were shown to predict therapeutic efficacy of MST in reducing suicidal ideation ([@bb0370]). In our study, baseline microstate dynamics (of all four states) predicted the therapeutic efficacy of MST in reducing suicidal ideation. Source localization revealed that all four microstates had in common the posterior cingulate cortex and the precuneus, regions linked with the default-mode network. This suggests that MST may be able to target the impaired default-mode network in treatment-resistant depression ([@bb0170]). The coil position of MST in this study supports this hypothesis as the greatest induced electrical field was over one of the hubs of the default-mode network, the dorsomedial prefrontal cortex. We suggest that MST modulates neural networks impaired in treatment-resistant depression but may not be as robust as ECT due to the sub-optimal induced electric field potentials.

As mentioned, patients that have previously received two or more courses of antidepressants with no clinical outcome are treatment-resistant. Detailed fMRI studies between healthy subjects and patients with and without treatment-resistant depression have indicated that different functional connectivity patterns may be associated with treatment-resistance ([@bb0415]; [@bb0410]; [@bb0400]), potentially due to the previous antidepressant exposure in treatment-resistant depression*.* Several neuroimaging studies have shown that treatment can change resting-state brain dynamics regardless of clinical outcome ([@bb0120]; [@bb0240]; [@bb0235]; [@bb0185]). In this study, a longer duration and lower frequency of microstates were observed in patients with treatment-resistant depression compared to healthy subjects. We link this effect to the neurotropic medications previously taken by these patients. Although the patients in this study did not respond to their previous treatments, we hypothesize that each treatment they received may have had an effect on global brain dynamics. It has been shown that benzodiazepines and antipsychotics can modulate microstate dynamics ([@bb0205]). Following seizure therapy, a larger increase in duration and decrease in frequency of microstates was observed in our study, suggesting that antidepressants and seizure therapy may modulate global brain dynamics in a similar manner. Considering the association of these changes to therapeutic outcome in seizure therapy, we hypothesize that seizure therapy overcomes the inadequacy of medications in treatment-resistant depression through a stronger impact on network dynamics. However, in the absence of a control group, i.e., patients without treatment-resistant depression and longitudinal assessments, it remains to be investigated whether this is an effect of treatment-resistance, medication, or both.

The higher efficacy of seizure therapy in treatment-resistant depression has been linked with the stimulation of thalamic oscillatory pacemakers and re-setting of neural dynamics ([@bb0090]). Studies have also highlighted the importance of temporal variability in affective and cognitive brain functions ([@bb0360]; [@bb0320]; [@bb0385]). A recent study showed a link between timescale-dependent and region-specific modulation of temporal complexity and the affective and cognitive impacts of seizure therapy ([@bb0095]). For example, association between change in complexity and improvement in depressive symptoms was localized to the fronto-central and parieto-occipital regions ([@bb0095]). In the current study, by observing the temporal stability of brain network dynamics rather than temporal complexity, we provide complimentary evidence suggesting that the therapeutic impact of seizure therapy is network-specific. States C and D were consistently associated with response to seizure therapy and these states were in part localized to the frontal, parietal and occipital regions.

There is strong evidence suggesting that seizure therapy impacts neuronal oscillations. Traditional power spectral density analysis has shown that the slowing of EEG oscillations following ECT is associated with improvement in depressive symptoms ([@bb0330]). Power spectral density analysis in our study also revealed increased slow wave activity following ECT. However, this effect was observed in both responders and non-responders. In comparison, microstate analysis illustrated that ECT responders show significant changes in certain microstates (A in duration and B, C, & D in frequency) while non-responders do not. In addition, changes in microstate dynamics were not associated with the increase in power of slow oscillations. Microstate analysis also demonstrated that patients with treatment-resistant depression reveal different global brain dynamics compared to healthy subjects and also that microstate D may play an important role in this difference. While we identified differences in microstate characteristics, no significant differences were observed in power between patients with treatment-resistant depression and healthy subjects. These findings suggest that microstate analysis provide additional and perhaps independent information compared to power spectral density analysis.

There are some limitations to this study. First, treatment-resistant depression may be too broad and heterogeneous to be treated in a homogenous manner. Although patients are grouped together under the definition of treatment-resistant depression (i.e., failed to respond to two or more antidepressants), as seen in this study, they still show heterogeneity in their response to treatments such as seizure therapy. This suggests that there is still considerable heterogeneity in the population of treatment-resistant depression which can translate to variability in the derived neurophysiological markers such as microstate characteristics. Results of this study will therefore need validation with a larger sample size. In addition, due to the small sample size, treatment parameters such as stimulation location (bilateral or unilateral for ECT) and frequency (for MST) could not be controlled. The potential effects these parameters may have on microstate characteristics need to be explored and validated by larger samples in future work. Preregistration of such future studies in advance of data collection and analysis is encouraged.

5. Conclusions {#s0145}
==============

The present study provides insight into the mechanism of action of successful seizure therapy for treatment-resistant depression using resting-state EEG microstate analysis. First, an increased duration and decreased frequency of microstates was observed in responders of seizure therapy, specifically ECT. This provides complementary evidence to recent neuroimaging studies which suggest that seizure therapy may stabilize global network dynamics in treatment-resistant depression. In MST, this modulation was a trend-level effect, implying that ECT may have a stronger impact on global neural networks than MST. Second, baseline microstate dynamics were indicative of MST-related improvement in cognition and suicidal ideation. Third, contrary to our hypothesis, we showed reduced global network dynamics in treatment-resistant depression when compared with healthy subjects. We hypothesized that this may be caused by previous antidepressants taken by these patients. Seizure therapy was shown to further reduce these dynamics and this reduction was associated with clinical response. This suggests that antidepressant medications and seizure therapy may have an analogous effect on network dynamics. However, only the modulation of global network dynamics by seizure therapy may be associated with clinical response. Finally, state-specific changes in microstate dynamics were observed in responders of seizure therapy. Microstates previously linked to resting-state networks known to be disrupted in depression (C and D), were associated with seizure therapy response. Further work is required to evaluate microstates as a therapeutic target in developing novel antidepressant treatments.
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[^1]: TRD: Treatment-Resistant Depression; ECT: electroconvulsive therapy; MST: magnetic seizure therapy.

[^2]: RUL UB: Right Unilateral Ultra-Brief Pulse Width; BL: Bitemporal (brief pulse width); DMPFC: Dorsomedial Prefrontal Cortex.

[^3]: Response for HRSD/BDI/MADRS/SSI defined as ≥ 50% improvement in score.
